Dear fellow Fools,if you did not read the report of a phase 1 clinical study presented in Vienna @ ESMO2012 already posted in the Fools universe, you can find the results here:http://www.fool.com/investing/businesswire/2012/09/30/prelim...My take is:1) Only 14 patients were included suffering from different cancer types - this study is definitely not powered to show hard clinical outcome.2) The 60 mg dose seems to be ideal in the Japanese study population included. 3) Tolerability looks okay although we have limited data.But why remained only 5 out of 14 patients on study after study completion although 11 of 14 patients had decreases in tumor size compared with baseline ?The study results are nice (be aware it was a phase 1 study), but in my opinion these results will not have any major impact on EXELs shareprice.fool on, marsuculix
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar